We were encouraged to see some very promising results from a Phase II clinical trial for high grade Neuroendocrine Carcinoma (NEC) patients, using a combination of Immunotherapy drugs. The results of this trial were recently presented at the American Association for Cancer Research Annual Meeting.
Click here for link to full press release
We welcome more research for these NEC patients and all NET Cancer patients and look forward to seeing more results based on real world experience.
Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.
In February our Co-founder and CEO, Simone Leyden handed over her Presidency of the International Neuroendocrine Cancer Alliance (INCA) to INCA member, Cathy Bouvier (NCUK). Congratulations to
Due to the COVID – 19 Pandemic the 17th Annual ENETs (physical) Conference was cancelled and in its place a Virtual Conference was held from
COSA held its 46th ASM in Adelaide 12 – 14 November 2019. There was an excellent attendance of multidisciplinary practitioners
Please add your voice to our Clinical Trials and Neuroendocrine Tumour (NET) survey.The Unicorn Foundation wants to see more clinical
All donations are tax deductible.
Registered Charity CFN 202607
© 2020 NeuroEndocrine Cancer Australia
Dive straight into the feedback!Login below and you can start commenting using your own user instantly